1.
Bioorg Med Chem Lett
; 14(13): 3525-9, 2004 Jul 05.
Artículo
en Inglés
| MEDLINE
| ID: mdl-15177466
RESUMEN
A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human beta3 adrenergic receptor agonist activity. SAR studies led to the identification of BMS-201620 (39), a potent beta3 full agonist (Ki = 93 nM, 93% activation). Based on its favorable safety profile, BMS-201620 was chosen for clinical evaluation.